Pharmacokinetic-driven Phase I study of DCC-2618, a pan-KIT and PDGFRα inhibitor, in patients with Gastrointestinal Stromal Tumor (GIST) and other solid tumors.
Mutation Profile of Drug Resistant GIST Patients Enrolled in the Phase 1 Study of DCC-2618
Safety profile of ripretinib, including impact of alopecia and palmar plantar erythrodysesthesia syndrome (PPES) on patient reported outcomes (PROs), in ≥4th line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.
Quality of life (QoL) and self reported function with ripretinib in ≥4th line therapy for patients with gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.
An open-label, multicenter, phase 1b/2 study of rebastinib in combination with paclitaxel in a dose expansion cohort to assess safety and preliminary efficacy in patients with advanced or metastatic endometrial cancer.
